AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9010612 — intervention group
Group type: EXPERIMENTAL
Intervention: RW94
Number of subjects: 12
Study 9010612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1894523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation and suctioning (three lung hyperinflation breaths at volumes of 12 cc/kg, 14 cc/kg, 16 cc/kg, or 18 cc/kg of lean body weight, followed by 10 seconds of continuous suction)
Number of subjects: 26
Study 1894523 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung hyperinflation and suctioning
Number of subjects: 26
Study 1894523 — intervention group
Group type: EXPERIMENTAL
Intervention: Suctioning
Number of subjects: 26
Study 6873137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 6 micrograms/kg (intravenous)
Number of subjects: 0
Study 6873137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.3 mg and 0.9 mg (oral)
Number of subjects: 0
Study 6873137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.9 mg b.d. for 3 days (oral)
Number of subjects: 0
Study 6873137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (alone and in combination with scopolamine)
Number of subjects: 0
Study 6873137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide 0.9 mg (oral)
Number of subjects: 0
Study 6873137 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (various doses)
Number of subjects: 0
Study 31797791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegilodecakin combined with pembrolizumab
Number of subjects: 0
Study 31797791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegilodecakin combined with nivolumab
Number of subjects: 0
Study 27935259 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey (MH) sinus irrigation
Number of subjects: 42
Study 27935259 — intervention group
Group type: COMPARATOR
Intervention: Saline (SAL) sinus irrigation
Number of subjects: 42
Study 27935259 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey (MH) sinus irrigation (in subset not receiving oral antibiotics/steroids)
Number of subjects: 42
Study 27935259 — intervention group
Group type: COMPARATOR
Intervention: Saline (SAL) sinus irrigation (in subset not receiving oral antibiotics/steroids)
Number of subjects: 42
Study 26993345 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal methylene blue (LMB) + Intense Pulsed Light (IPL)
Number of subjects: 35
Study 26993345 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL) alone
Number of subjects: 35
Study 26993345 — intervention group
Group type: EXPERIMENTAL
Intervention: LMB + IPL
Number of subjects: 35
Study 26993345 — intervention group
Group type: COMPARATOR
Intervention: IPL alone
Number of subjects: 35
Study 25128002 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 500
Study 25128002 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training plus solifenacin (5 mg once daily)
Number of subjects: 500
Study 22899693 — intervention group
Group type: EXPERIMENTAL
Intervention: xylitol‐wipe
Number of subjects: 44
Study 22899693 — intervention group
Group type: COMPARATOR
Intervention: placebo‐wipe
Number of subjects: 44
Study 19640952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, carbohydrate-free diet (H diet; 30% protein, 0% carbohydrate, 70% fat)
Number of subjects: 10
Study 19640952 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (N condition; 12% protein, 55% carbohydrate, 33% fat)
Number of subjects: 10
Study 17210771 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole at 800 mg/day as an oral suspension in divided doses
Number of subjects: 12
Study 10863225 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented betamethasone dipropionate 0.05% cream once daily in the first and third weeks and calcipotriene 0.005% ointment twice daily in the second and fourth weeks
Number of subjects: 52
Study 10863225 — intervention group
Group type: COMPARATOR
Intervention: Daily augmented betamethasone dipropionate 0.05% cream for 4 weeks
Number of subjects: 52
Study 9176849 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 31
Study 9176849 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 31
Study 1356176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg every 12 h via nasogastric tube until 24 h after extubation (n = 38)
Number of subjects: 70
Study 1356176 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 h via nasogastric tube until 24 h after extubation (n = 32)
Number of subjects: 70
Study 4047067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (oral treatment)
Number of subjects: 15
Study 4047067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (after exercise-induced asthma)
Number of subjects: 15
Study 4047067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (pharmacokinetics)
Number of subjects: 15
Study 4047067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (overall efficacy)
Number of subjects: 15
Study 4047067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxyphylline (safety)
Number of subjects: 15
Study 30446432 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum from incident-T2DM patients
Number of subjects: 215
Study 30446432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 4 h-postprandial PBMCs from incident-T2DM patients
Number of subjects: 215
Study 30446432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting/postprandial levels of splicing machinery components in PBMCs
Number of subjects: 215
Study 26993881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg/3 mL intramuscular)
Number of subjects: 1644
Study 26993881 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g/100 mL intravenous)
Number of subjects: 1644
Study 26993881 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg intravenous)
Number of subjects: 1644
Study 26993881 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 1644
Study 26993881 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 1644
Study 26993881 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 1644
Study 24079852 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 70 mg
Number of subjects: 198
Study 24079852 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 198
Study 24079852 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 198
Study 24079852 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 280 mg
Number of subjects: 198
Study 24079852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 22313885 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Huayu herbs plus classic Western medical treatment (treatment group)
Number of subjects: 98
Study 22313885 — intervention group
Group type: COMPARATOR
Intervention: Classic Western medical treatment (control group)
Number of subjects: 98
Study 20040164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 0
Study 20040164 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 18404579 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-finger method
Number of subjects: 50
Study 18404579 — intervention group
Group type: COMPARATOR
Intervention: Usual memorization method
Number of subjects: 50
Study 15844715 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study 15844715 — intervention group
Group type: EXPERIMENTAL
Intervention: No-fiber polymeric diet
Number of subjects: 0
Study 15844715 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 0
Study 12431146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation 3 hours after catheter or sheath removal
Number of subjects: 110
Study 12431146 — intervention group
Group type: COMPARATOR
Intervention: Ambulation 6 hours after catheter or sheath removal
Number of subjects: 110
Study 12431146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (3-H and 6-H)
Number of subjects: 110
Study 12431146 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulation 3 hours after diagnostic angiography
Number of subjects: 110
Study 12431146 — intervention group
Group type: COMPARATOR
Intervention: Ambulation 6 hours after diagnostic angiography
Number of subjects: 110
Study 12431146 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation after angiography
Number of subjects: 110
Study 10488294 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil administered at the conclusion of the surgical procedure
Number of subjects: 110
Study 10488294 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at the conclusion of the surgical procedure
Number of subjects: 110
Study 8814687 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection-line involvement
Number of subjects: 699
Study 8814687 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 and T4 stage
Number of subjects: 699
Study 8814687 — intervention group
Group type: EXPERIMENTAL
Intervention: N(+) stage
Number of subjects: 699
Study 8814687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour differentiation
Number of subjects: 699
Study 8814687 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of resection-line involvement
Number of subjects: 699
Study 1755934 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation with placebo
Number of subjects: 12
Study 1755934 — intervention group
Group type: COMPARATOR
Intervention: Biperiden (4 mg)
Number of subjects: 12
Study 31860537 — intervention group
Group type: EXPERIMENTAL
Intervention: 300,000 IU of vitamin D3 once (stoss group)
Number of subjects: 44
Study 31860537 — intervention group
Group type: COMPARATOR
Intervention: 50,000 IU of vitamin D3 once weekly for 6 weeks (standard of care, SOC group)
Number of subjects: 44
Study 30809995 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability training (CST) on an unstable support surface (USS)
Number of subjects: 29
Study 30809995 — intervention group
Group type: COMPARATOR
Intervention: Core stability training (CST) on a stable support surface (SSS)
Number of subjects: 29
Study 28155018 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding My Way online intervention
Number of subjects: 191
Study 28155018 — intervention group
Group type: COMPARATOR
Intervention: Information-only online control
Number of subjects: 191
Study 25909236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with 1.2 g ω‐3 fatty acids per day
Number of subjects: 60
Study 25909236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 25909236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received warm compresses, lid massage, and artificial tear substitutes
Number of subjects: 60
Study 25909236 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 23506367 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco deprived condition (n = 51)
Number of subjects: 120
Study 23506367 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived condition (n = 69)
Number of subjects: 120
Study 21564406 — intervention group
Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone caproate 250 mg intramuscularly weekly from 16 weeks' gestation to 37 weeks' gestation
Number of subjects: 100
Study 21564406 — intervention group
Group type: COMPARATOR
Intervention: Routine perinatal care
Number of subjects: 100
Study 19241234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushrim-activated, power-assisted wheelchair (PPW)
Number of subjects: 0
Study 19241234 — intervention group
Group type: COMPARATOR
Intervention: Power wheelchair
Number of subjects: 0
Study 17267789 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic-focused psychodynamic psychotherapy
Number of subjects: 49
Study 17267789 — intervention group
Group type: COMPARATOR
Intervention: Applied relaxation training
Number of subjects: 49
Study 16105869 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-based HAART (n = 32)
Number of subjects: 68
Study 16105869 — intervention group
Group type: COMPARATOR
Intervention: Non-PI-based HAART (n = 36)
Number of subjects: 68
Study 16105869 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (general)
Number of subjects: 68
Study 12379156 — intervention group
Group type: EXPERIMENTAL
Intervention: Frisolac Allergycare (FAC)
Number of subjects: 30
Study 12379156 — intervention group
Group type: COMPARATOR
Intervention: Nutramigen (NUT)
Number of subjects: 30
Study 10206131 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective gastric lavage before the first feed (227 neonates)
Number of subjects: 502
Study 10206131 — intervention group
Group type: COMPARATOR
Intervention: No gastric lavage prior to feeds (275 neonates)
Number of subjects: 502
Study 7762843 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (up to two IV boluses of 5 mg followed by IV morphine PCA)
Number of subjects: 51
Study 7762843 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (up to two IV boluses of 30 mg followed by IV ketorolac PCA)
Number of subjects: 51
Study 7762843 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (Group 1)
Number of subjects: 51
Study 7762843 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (Group 2)
Number of subjects: 51
Study 7762843 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and Ketorolac (Groups 1 and 2)
Number of subjects: 51
Study 2308758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of morphine (PCA)
Number of subjects: 58
Study 2308758 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of morphine
Number of subjects: 58
Study 6446011 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 6446011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30740014 — intervention group
Group type: EXPERIMENTAL
Intervention: Valveless Trocar System (VTS)
Number of subjects: 200
Study 30740014 — intervention group
Group type: COMPARATOR
Intervention: Standard Trocar
Number of subjects: 200
Study 27640872 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic review
Number of subjects: 187
Study 27640872 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction intervention
Number of subjects: 187
Study 27640872 — intervention group
Group type: COMPARATOR
Intervention: Antipsychotic review and social interaction
Number of subjects: 187
Study 25520427 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial chemoprevention
Number of subjects: 196
Study 25520427 — intervention group
Group type: COMPARATOR
Intervention: No chemoprevention
Number of subjects: 196
Study 25520427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-erythrocytic antigens
Number of subjects: 196
Study 25520427 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-stage antigens
Number of subjects: 196
Study 24163235 — intervention group
Group type: COMPARATOR
Intervention: Telephone health education (THE)
Number of subjects: 52
Study 24163235 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling (TC)
Number of subjects: 52
Study 24163235 — intervention group
Group type: EXPERIMENTAL
Intervention: Videophone counselling (VC)
Number of subjects: 52
Study 21168112 — intervention group
Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 30
Study 21168112 — intervention group
Group type: COMPARATOR
Intervention: Light touch on the SP6 acupoint (Control)
Number of subjects: 30
Study 19168412 — intervention group
Group type: EXPERIMENTAL
Intervention: Test ciprofloxacin (500 mg)
Number of subjects: 14
Study 19168412 — intervention group
Group type: COMPARATOR
Intervention: Reference ciprofloxacin (500 mg)
Number of subjects: 14
Study 16737668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 86
Study 16737668 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 16737668 — intervention group
Group type: COMPARATOR
Intervention: Acustimulation wristbands
Number of subjects: 86
Study 15541982 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivostat (autologous fibrin sealant)
Number of subjects: 40
Study 11378316 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 212
Study 11378316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 212
Study 11378316 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 212
Study 9238875 — intervention group
Group type: EXPERIMENTAL
Intervention: PPi/TCS dentifrice (5.0% soluble pyrophosphate/0.145% fluoride as NaF/silica abrasive/0.28% triclosan)
Number of subjects: 544
Study 9238875 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn/TCS dentifrice (0.5% zinc citrate trihydrate/0.15% fluoride as sodium monofluorophosphate/silica abrasive/0.20% triclosan)
Number of subjects: 544
Study 9238875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gan/TCS dentifrice (2.0% Gantrez acid copolymer/0.145% fluoride as NaF/silica abrasive/0.30% triclosan)
Number of subjects: 544
Study 9238875 — intervention group
Group type: EXPERIMENTAL
Intervention: PPi/TCS dentifrice
Number of subjects: 544
Study 9238875 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (0.145% fluoride as NaF/silica abrasive)
Number of subjects: 544
Study 8431747 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic solution at 42 degrees C
Number of subjects: 136
Study 8431747 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic solution at 10 degrees C
Number of subjects: 136
Study 8431747 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic solution at 18 degrees C
Number of subjects: 136
Study 8431747 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic solution at 37 degrees C
Number of subjects: 136
Study 3038415 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once-a-day
Number of subjects: 205
Study 3038415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 29198543 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitors of gastric acidity (H2 blockers or proton pump inhibitors)
Number of subjects: 743
Study 27654495 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Parking (FP)
Number of subjects: 138
Study 27654495 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 138
Study 25242051 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E Cancer Prevention Trial (SELECT)
Number of subjects: 32340
Study 22541755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moprid® (5 mg mosapride citrate tablets)
Number of subjects: 23
Study 22541755 — intervention group
Group type: COMPARATOR
Intervention: Gasmotin® (5 mg mosapride citrate tablets)
Number of subjects: 23
Study 21246849 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance acupuncture on Jiantong point
Number of subjects: 60
Study 21246849 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture on Shuigou (GV 26), Neiguan (PC 6), Tongli (HT 5), Zusanlti (ST 36), Xuanzhong (GB 39) and others
Number of subjects: 60
Study 21246849 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance acupuncture
Number of subjects: 60
Study 21246849 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 60
Study 21246849 — intervention group
Group type: COMPARATOR
Intervention: Balance acupuncture vs Conventional acupuncture
Number of subjects: 60
Study 17589809 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVT) 4 mg
Number of subjects: 61
Study 17589809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16279574 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage randomized phase II clinical trial design
Number of subjects: 0
Study 16279574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive sample size at the second stage
Number of subjects: 0
Study 12381902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 and raltitrexed 2.5 mg/m2 on day 1 and Levofolinic acid 250 mg/m2 and 5‐fluorouracil 900 mg/m2 on day 2 (arm A)
Number of subjects: 61
Study 12381902 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 65 mg/m2 and methotrexate 500 mg/m2 on day 1 and Levofolinic acid 250 mg/m2 and 5‐fluorouracil 800 mg/m2 on day 2 (arm B)
Number of subjects: 61
Study 10089866 — intervention group
Group type: EXPERIMENTAL
Intervention: Mode switching algorithm
Number of subjects: 0
Study 10089866 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8524988 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic task
Number of subjects: 40
Study 8524988 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural change (standing)
Number of subjects: 40
Study 2177158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ACTH 4-10
Number of subjects: 18
Study 2177158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7410535 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 10
Study 7410535 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 10
Study 7410535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30746674 — intervention group
Group type: EXPERIMENTAL
Intervention: Training by junior teacher
Number of subjects: 66
Study 30746674 — intervention group
Group type: COMPARATOR
Intervention: Training by senior teacher
Number of subjects: 66
Study 27520594 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar-powered odour-baited mosquito trapping systems (SMoTS) installed in 4358 households during the roll-out from June 3, 2013, to May 16, 2015.
Number of subjects: 34041
Study 27520594 — intervention group
Group type: COMPARATOR
Intervention: Non-intervened clusters (no SMoTS installed).
Number of subjects: 34041
Study 27520594 — intervention group
Group type: EXPERIMENTAL
Intervention: SMoTS clusters (intervened).
Number of subjects: 34041
Study 27520594 — intervention group
Group type: COMPARATOR
Intervention: Non-intervened clusters.
Number of subjects: 34041
Study 24739910 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% water-soluble propolis extract
Number of subjects: 0
Study 24739910 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline
Number of subjects: 0